Cracking The Code: Understanding Analyst Reviews For Exact Sciences
Portfolio Pulse from Benzinga Insights
Exact Sciences (NASDAQ:EXAS) has received mixed analyst ratings over the past three months, with a trend towards lowering price targets. The average 12-month price target is now $74, down from $84.86. Analysts have adjusted their ratings in response to market dynamics and company performance. Exact Sciences, known for its cancer screening products, has shown revenue growth but lags behind industry peers. The company's financials reveal challenges in ROE and ROA, despite a strong net margin and prudent debt management.
September 12, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Exact Sciences has received a range of analyst ratings, with a trend towards lowering price targets. The average 12-month price target is now $74, down from $84.86. Analysts have adjusted their ratings in response to market dynamics and company performance.
The trend of analysts lowering their price targets for Exact Sciences suggests a negative short-term outlook. The average price target has decreased significantly, indicating reduced expectations for the stock's performance. This is likely to impact investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100